Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. In 2020 alone, online searches for chin enhancement increased by 185 percent, reinforcing the emerging patient need for a product like Restylane Defyne, which is the first and only chin filler to demonstrate results across a wide range of participants, including participants with all skin types, male subjects and subjects over the age of 52. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 2016 by the FDA for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds, in subjects over age 21.
Read more at PR Newswire >>